Is Eradicating Mast Cells a Feasible Strategy for Systemic Mastocytosis?
Scientists have proposed the eradication of mast cells as a therapeutic strategy to fight against mast cell activation disorders.
Scientists have proposed the eradication of mast cells as a therapeutic strategy to fight against mast cell activation disorders.
Researchers reported the case of a patient who had acute mast cell leukemia preceded by a malignant mediastinal germ cell tumor and published their findings in Cancer Management and Research. Systemic mastocytosis (SM) occurs when mast cells invade the bone marrow as well as other organs in the body. Mast cell leukemia is a subtype…
A novel genotype was identified in a patient with systemic mastocytosis (SM) and published in a case report in Cancer Genetics. “This case provides evidence that MCL [mast cell leukemia] can have wide spectrum of genetic abnormalities as well as accumulation of mutations in various genes including BRAF,” the authors said. The study demonstrated coexistent…
People with rare diseases who live in the United States have a poor health-related quality of life and experience significant stigma, according to a study published in the Orphanet Journal of Rare Diseases. A rare disease in the United States can be defined as any disease in which the prevalence is less than 200,000 cases.…
Researchers described the case study of a patient with systemic mastocytosis (SM) who was administered anesthesia for a cesarean section birth delivery and published their results in the International Journal of Obstetric Anesthesia. The case study as presented by Alex and colleagues from the George Eliot Hospital NHS Trust in Nuneaton, England was about a…
After countless colonoscopies and multiple steroid treatments, biopsies determined I had abnormally large counts of white blood cells.
Cogent Biosciences announced an upcoming presentation of initial data from the phase 2 APEX trial on bezuclastinib for patients with advanced systemic mastocytosis (SM). The presentation, announced via news release, will occur at the European Hematology Association (EHA) Annual Congress on June 10, 2022. “There is a significant unmet need for novel, safe, and effective treatment…
Patients with systemic mastocytosis (SM) tend to have elevated urinary levels of mast cell metabolites and their symptoms mitigate with mastocyte control drugs, according to a new study published in the Journal of Allergy and Clinical Immunology. In contrast, patients with hereditary alpha-tryptasemia, despite showing mast cell activation symptoms, do not have mast cell metabolites in…
Researchers have proposed a possible explanation for the variation in FcεRI expression during the development of mast cells, suggesting that external stimuli regulate the FcεRI expression of mast cell progenitors, Many diseases, such as asthma and systemic mastocytosis, are driven by mast cells. The current understanding is that mast cell progenitors exhibit low FcεRI expression,…
It is possible to diagnose systemic mastocytosis through basic morphology and a restricted immunohistochemical panel, according to a new study published in the journal Human Pathology. “Of note, pathologist(s) should recognize the different morphological variants of the disease and include the adequate markers when requesting immunohistochemical studies,” the authors of the study wrote. It is…